An analogy between licensing and corporate investment facilitates the determination of fair license terms and displays whether the deal creates value for both parties. Clumsy and out of date rules of thumb are not needed anymore.
By Ralph Villiger, partner at A vance, Basel GmbH
[inlinead]
|
|
Have Your Say Rate this feature and give us your feedback in the comments section below |
Insights from the world’s foremost thought leaders delivered to your inbox.
2022-10-18
02:00 PM - 03:00 PM BST
Join us to hear from the most influential people in pharma today, as voted for by you
2022-06-01
04:30 PM - 05:30 PM CET
In this panel discussion with experts from 4G Clinical, THREAD Research and World Courier, learn how...
2022-04-28
01:00 PM - 02:00 PM EST
This Pharma IQ webinar with AIQ explores how AI-assisted analysis of radiological scans enhances the...
